APO Research
Talk to an analyst

APO RESEARCH · REPORT

Combination Vaccine and Multivalent Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Combination Vaccine and Multivalent Vaccine Market Analysis and Forecast 2026-2032

27 December 2025218 pages

Choose your research edition.

Industry ResearchCombination Vaccine and Multivalent Vaccine Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal Combination Vaccine and Multivalent Vaccine Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Combination Vaccine and Multivalent Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Combination Vaccine and Multivalent Vaccine Market Outlook and Growth Opportunities 2026213 pages · $4,250 USDMarket Analysis & ForecastGlobal Combination Vaccine and Multivalent Vaccine Market Analysis and Forecast 2026-2032218 pages · $4,950 USD

Market perspective

The global Combination Vaccine and Multivalent Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Combination Vaccine and Multivalent Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Combination Vaccine and Multivalent Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Combination Vaccine and Multivalent Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Combination Vaccine and Multivalent Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Combination Vaccine and Multivalent Vaccine include BioNTech, Dynavax, Moderna, Novavax, Pfizer, Sanofi Pasteur, AIM Bio, Beijing Institute of Biological Products and Chengdu Institute of Biological Products, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Combination Vaccine and Multivalent Vaccine, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Combination Vaccine and Multivalent Vaccine, also provides the revenue of main regions and countries. Of the upcoming market potential for Combination Vaccine and Multivalent Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Combination Vaccine and Multivalent Vaccine revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Combination Vaccine and Multivalent Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Combination Vaccine and Multivalent Vaccine revenue, projected growth trends, production technology, application and end-user industry.

Combination Vaccine and Multivalent Vaccine Segment by Company

BioNTech

Dynavax

Moderna

Novavax

Pfizer

Sanofi Pasteur

AIM Bio

Beijing Institute of Biological Products

Chengdu Institute of Biological Products

Antejin Biotechnology

GlaxoSmithKline

Kangtai Bio

Sinovac

Lanzhou Institute of Biological Products

Minhai Biological

Merck & Co.

Wanbangde Pharmaceutical

Wantai Biological

Walvax

Wuhan Institute of Biological Products

Zhifei Biological

Sino Biopharm

Combination Vaccine and Multivalent Vaccine Segment by Type

Combination Vaccine

Multivalent Vaccine

Combination Vaccine and Multivalent Vaccine Segment by Application

Hospital

Centers for Disease Control and Prevention

Others

Combination Vaccine and Multivalent Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Combination Vaccine and Multivalent Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Combination Vaccine and Multivalent Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Combination Vaccine and Multivalent Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Combination Vaccine and Multivalent Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Combination Vaccine and Multivalent Vaccine company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Combination Vaccine and Multivalent Vaccine revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Combination Vaccine and Multivalent Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Combination Vaccine Major Player Table 3. Multivalent Vaccine Major Player Table 4. Global Combination Vaccine and Multivalent Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Centers for Disease Control and Prevention Major Player Table 7. Others Major Player Table 8. Combination Vaccine and Multivalent Vaccine Industry Trends Table 9. Combination Vaccine and Multivalent Vaccine Industry Drivers Table 10. Combination Vaccine and Multivalent Vaccine Industry Opportunities and Challenges Table 11. Combination Vaccine and Multivalent Vaccine Industry Restraints Table 12. Global Combination Vaccine and Multivalent Vaccine Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Combination Vaccine and Multivalent Vaccine Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Combination Vaccine and Multivalent Vaccine Market Share by Region (2021-2026) Table 15. Global Combination Vaccine and Multivalent Vaccine Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Combination Vaccine and Multivalent Vaccine Market Share by Region (2027-2032) Table 17. Global Combination Vaccine and Multivalent Vaccine Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Combination Vaccine and Multivalent Vaccine Revenue Market Share by Players (2021-2026) Table 19. Global Combination Vaccine and Multivalent Vaccine Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Combination Vaccine and Multivalent Vaccine Key Players Headquarters & Area Served Table 21. Global Combination Vaccine and Multivalent Vaccine Players, Product Type & Application Table 22. Global Combination Vaccine and Multivalent Vaccine Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Combination Vaccine and Multivalent Vaccine by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Combination Vaccine and Multivalent Vaccine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Combination Vaccine and Multivalent Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Combination Vaccine and Multivalent Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Combination Vaccine and Multivalent Vaccine Revenue Market Share by Type (2021-2026) Table 29. Global Combination Vaccine and Multivalent Vaccine Revenue Market Share by Type (2027-2032) Table 30. Global Combination Vaccine and Multivalent Vaccine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Combination Vaccine and Multivalent Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Combination Vaccine and Multivalent Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Combination Vaccine and Multivalent Vaccine Revenue Market Share by Application (2021-2026) Table 34. Global Combination Vaccine and Multivalent Vaccine Revenue Market Share by Application (2027-2032) Table 35. BioNTech Company Information Table 36. BioNTech Business Overview Table 37. BioNTech Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. BioNTech Combination Vaccine and Multivalent Vaccine Product Portfolio Table 39. BioNTech Recent Development Table 40. Dynavax Company Information Table 41. Dynavax Business Overview Table 42. Dynavax Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Dynavax Combination Vaccine and Multivalent Vaccine Product Portfolio Table 44. Dynavax Recent Development Table 45. Moderna Company Information Table 46. Moderna Business Overview Table 47. Moderna Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Moderna Combination Vaccine and Multivalent Vaccine Product Portfolio Table 49. Moderna Recent Development Table 50. Novavax Company Information Table 51. Novavax Business Overview Table 52. Novavax Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Novavax Combination Vaccine and Multivalent Vaccine Product Portfolio Table 54. Novavax Recent Development Table 55. Pfizer Company Information Table 56. Pfizer Business Overview Table 57. Pfizer Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Pfizer Combination Vaccine and Multivalent Vaccine Product Portfolio Table 59. Pfizer Recent Development Table 60. Sanofi Pasteur Company Information Table 61. Sanofi Pasteur Business Overview Table 62. Sanofi Pasteur Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Sanofi Pasteur Combination Vaccine and Multivalent Vaccine Product Portfolio Table 64. Sanofi Pasteur Recent Development Table 65. AIM Bio Company Information Table 66. AIM Bio Business Overview Table 67. AIM Bio Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. AIM Bio Combination Vaccine and Multivalent Vaccine Product Portfolio Table 69. AIM Bio Recent Development Table 70. Beijing Institute of Biological Products Company Information Table 71. Beijing Institute of Biological Products Business Overview Table 72. Beijing Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Beijing Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio Table 74. Beijing Institute of Biological Products Recent Development Table 75. Chengdu Institute of Biological Products Company Information Table 76. Chengdu Institute of Biological Products Business Overview Table 77. Chengdu Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Chengdu Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio Table 79. Chengdu Institute of Biological Products Recent Development Table 80. Antejin Biotechnology Company Information Table 81. Antejin Biotechnology Business Overview Table 82. Antejin Biotechnology Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Antejin Biotechnology Combination Vaccine and Multivalent Vaccine Product Portfolio Table 84. Antejin Biotechnology Recent Development Table 85. GlaxoSmithKline Company Information Table 86. GlaxoSmithKline Business Overview Table 87. GlaxoSmithKline Combination Vaccine and Multivalent Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. GlaxoSmithKline Combination Vaccine and Multivalent Vaccine Product Portfolio Table 89. GlaxoSmithKline Recent Development Table 90. Kangtai Bio Company Information Table 91. Kangtai Bio Business Overview Table 92. Kangtai Bio Combination Vaccine and Multivalent Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Kangtai Bio Combination Vaccine and Multivalent Vaccine Product Portfolio Table 94. Kangtai Bio Recent Development Table 95. Sinovac Company Information Table 96. Sinovac Business Overview Table 97. Sinovac Combination Vaccine and Multivalent Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Sinovac Combination Vaccine and Multivalent Vaccine Product Portfolio Table 99. Sinovac Recent Development Table 100. Lanzhou Institute of Biological Products Company Information Table 101. Lanzhou Institute of Biological Products Business Overview Table 102. Lanzhou Institute of Biological Products Combination Vaccine and Multivalent Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Lanzhou Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio Table 104. Lanzhou Institute of Biological Products Recent Development Table 105. Minhai Biological Company Information Table 106. Minhai Biological Business Overview Table 107. Minhai Biological Combination Vaccine and Multivalent Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Minhai Biological Combination Vaccine and Multivalent Vaccine Product Portfolio Table 109. Minhai Biological Recent Development Table 110. Merck & Co. Company Information Table 111. Merck & Co. Business Overview Table 112. Merck & Co. Combination Vaccine and Multivalent Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Merck & Co. Combination Vaccine and Multivalent Vaccine Product Portfolio Table 114. Merck & Co. Recent Development Table 115. Wanbangde Pharmaceutical Company Information Table 116. Wanbangde Pharmaceutical Business Overview Table 117. Wanbangde Pharmaceutical Combination Vaccine and Multivalent Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Wanbangde Pharmaceutical Combination Vaccine and Multivalent Vaccine Product Portfolio Table 119. Wanbangde Pharmaceutical Recent Development Table 120. Wantai Biological Company Information Table 121. Wantai Biological Business Overview Table 122. Wantai Biological Combination Vaccine and Multivalent Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Wantai Biological Combination Vaccine and Multivalent Vaccine Product Portfolio Table 124. Wantai Biological Recent Development Table 125. Walvax Company Information Table 126. Walvax Business Overview Table 127. Walvax Combination Vaccine and Multivalent Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 128. Walvax Combination Vaccine and Multivalent Vaccine Product Portfolio Table 129. Walvax Recent Development Table 130. Wuhan Institute of Biological Products Company Information Table 131. Wuhan Institute of Biological Products Business Overview Table 132. Wuhan Institute of Biological Products Combination Vaccine and Multivalent Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 133. Wuhan Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio Table 134. Wuhan Institute of Biological Products Recent Development Table 135. Zhifei Biological Company Information Table 136. Zhifei Biological Business Overview Table 137. Zhifei Biological Combination Vaccine and Multivalent Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 138. Zhifei Biological Combination Vaccine and Multivalent Vaccine Product Portfolio Table 139. Zhifei Biological Recent Development Table 140. Sino Biopharm Company Information Table 141. Sino Biopharm Business Overview Table 142. Sino Biopharm Combination Vaccine and Multivalent Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 143. Sino Biopharm Combination Vaccine and Multivalent Vaccine Product Portfolio Table 144. Sino Biopharm Recent Development Table 145. North America Combination Vaccine and Multivalent Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 146. North America Combination Vaccine and Multivalent Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 147. North America Combination Vaccine and Multivalent Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 148. North America Combination Vaccine and Multivalent Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 149. North America Combination Vaccine and Multivalent Vaccine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 150. North America Combination Vaccine and Multivalent Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 151. North America Combination Vaccine and Multivalent Vaccine Revenue by Country (US$ Million) & (2027-2032) Table 152. Europe Combination Vaccine and Multivalent Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 153. Europe Combination Vaccine and Multivalent Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 154. Europe Combination Vaccine and Multivalent Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 155. Europe Combination Vaccine and Multivalent Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 156. Europe Combination Vaccine and Multivalent Vaccine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 157. Europe Combination Vaccine and Multivalent Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 158. Europe Combination Vaccine and Multivalent Vaccine Revenue by Country (US$ Million) & (2027-2032) Table 159. China Combination Vaccine and Multivalent Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 160. China Combination Vaccine and Multivalent Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 161. China Combination Vaccine and Multivalent Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 162. China Combination Vaccine and Multivalent Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 163. Asia Combination Vaccine and Multivalent Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 164. Asia Combination Vaccine and Multivalent Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 165. Asia Combination Vaccine and Multivalent Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 166. Asia Combination Vaccine and Multivalent Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 167. Asia Combination Vaccine and Multivalent Vaccine Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 168. Asia Combination Vaccine and Multivalent Vaccine Revenue by Region (US$ Million) & (2021-2026) Table 169. Asia Combination Vaccine and Multivalent Vaccine Revenue by Region (US$ Million) & (2027-2032) Table 170. SAMEA Combination Vaccine and Multivalent Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 171. SAMEA Combination Vaccine and Multivalent Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 172. SAMEA Combination Vaccine and Multivalent Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 173. SAMEA Combination Vaccine and Multivalent Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 174. SAMEA Combination Vaccine and Multivalent Vaccine Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 175. SAMEA Combination Vaccine and Multivalent Vaccine Revenue by Country (2021-2026) & (US$ Million) Table 176. SAMEA Combination Vaccine and Multivalent Vaccine Revenue by Country (US$ Million) & (2027-2032) Table 177. Research Programs/Design for This Report Table 178. Authors List of This Report Table 179. Secondary Sources Table 180. Primary Sources List of Figures Figure 1. Combination Vaccine and Multivalent Vaccine Image Figure 2. Global Combination Vaccine and Multivalent Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Combination Vaccine and Multivalent Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Combination Vaccine Image Figure 5. Multivalent Vaccine Image Figure 6. Global Combination Vaccine and Multivalent Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Combination Vaccine and Multivalent Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Centers for Disease Control and Prevention Image Figure 10. Others Image Figure 11. Global Combination Vaccine and Multivalent Vaccine Market Size (US$ Million) & (2021-2032) Figure 12. Global Combination Vaccine and Multivalent Vaccine Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Combination Vaccine and Multivalent Vaccine Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Combination Vaccine and Multivalent Vaccine Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Combination Vaccine and Multivalent Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Combination Vaccine and Multivalent Vaccine Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Combination Vaccine and Multivalent Vaccine Revenue Market Share by Type (2021-2032) Figure 19. Global Combination Vaccine and Multivalent Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Combination Vaccine and Multivalent Vaccine Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Combination Vaccine and Multivalent Vaccine Revenue Market Share by Application (2021-2032) Figure 22. North America Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Combination Vaccine and Multivalent Vaccine Revenue Share by Type (2021-2032) Figure 24. North America Combination Vaccine and Multivalent Vaccine Revenue Share by Application (2021-2032) Figure 25. North America Combination Vaccine and Multivalent Vaccine Revenue Share by Country (2021-2032) Figure 26. United States Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Combination Vaccine and Multivalent Vaccine Revenue Share by Type (2021-2032) Figure 31. Europe Combination Vaccine and Multivalent Vaccine Revenue Share by Application (2021-2032) Figure 32. Europe Combination Vaccine and Multivalent Vaccine Revenue Share by Country (2021-2032) Figure 33. Germany Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Combination Vaccine and Multivalent Vaccine Revenue Share by Type (2021-2032) Figure 43. China Combination Vaccine and Multivalent Vaccine Revenue Share by Application (2021-2032) Figure 44. Asia Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Combination Vaccine and Multivalent Vaccine Revenue Share by Type (2021-2032) Figure 46. Asia Combination Vaccine and Multivalent Vaccine Revenue Share by Application (2021-2032) Figure 47. Asia Combination Vaccine and Multivalent Vaccine Revenue Share by Region (2021-2032) Figure 48. Japan Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Combination Vaccine and Multivalent Vaccine Revenue Share by Type (2021-2032) Figure 56. SAMEA Combination Vaccine and Multivalent Vaccine Revenue Share by Application (2021-2032) Figure 57. SAMEA Combination Vaccine and Multivalent Vaccine Revenue Share by Country (2021-2032) Figure 58. Brazil Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Combination Vaccine and Multivalent Vaccine Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Combination Vaccine
  • Multivalent Vaccine
Applications
  • Hospital
  • Centers for Disease Control and Prevention
  • Others
Companies covered
  • BioNTech
  • Dynavax
  • Moderna
  • Novavax
  • Pfizer
  • Sanofi Pasteur
  • AIM Bio
  • Beijing Institute of Biological Products
  • Chengdu Institute of Biological Products
  • Antejin Biotechnology
  • GlaxoSmithKline
  • Kangtai Bio
  • Sinovac
  • Lanzhou Institute of Biological Products
  • Minhai Biological
  • Merck & Co.
  • Wanbangde Pharmaceutical
  • Wantai Biological
  • Walvax
  • Wuhan Institute of Biological Products
  • Zhifei Biological
  • Sino Biopharm

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Combination Vaccine and Multivalent Vaccine Market by Type
  3. 1.2.1 Global Combination Vaccine and Multivalent Vaccine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Combination Vaccine
  5. 1.2.3 Multivalent Vaccine
  6. 1.3 Combination Vaccine and Multivalent Vaccine Market by Application
  7. 1.3.1 Global Combination Vaccine and Multivalent Vaccine Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Centers for Disease Control and Prevention
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Combination Vaccine and Multivalent Vaccine Market Dynamics
  1. 2.1 Combination Vaccine and Multivalent Vaccine Industry Trends
  2. 2.2 Combination Vaccine and Multivalent Vaccine Industry Drivers
  3. 2.3 Combination Vaccine and Multivalent Vaccine Industry Opportunities and Challenges
  4. 2.4 Combination Vaccine and Multivalent Vaccine Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Combination Vaccine and Multivalent Vaccine Market Perspective (2021-2032)
  2. 3.2 Global Combination Vaccine and Multivalent Vaccine Growth Trends by Region
  3. 3.2.1 Global Combination Vaccine and Multivalent Vaccine Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Combination Vaccine and Multivalent Vaccine Market Size by Region (2021-2026)
  5. 3.2.3 Global Combination Vaccine and Multivalent Vaccine Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Combination Vaccine and Multivalent Vaccine Revenue by Players
  2. 4.1.1 Global Combination Vaccine and Multivalent Vaccine Revenue by Players (2021-2026)
  3. 4.1.2 Global Combination Vaccine and Multivalent Vaccine Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Combination Vaccine and Multivalent Vaccine Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Combination Vaccine and Multivalent Vaccine Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Combination Vaccine and Multivalent Vaccine Key Players Headquarters & Area Served
  7. 4.4 Global Combination Vaccine and Multivalent Vaccine Players, Product Type & Application
  8. 4.5 Global Combination Vaccine and Multivalent Vaccine Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Combination Vaccine and Multivalent Vaccine Market CR5 and HHI
  11. 4.6.3 2025 Combination Vaccine and Multivalent Vaccine Tier 1, Tier 2, and Tier 3
5 Combination Vaccine and Multivalent Vaccine Market Size by Type
  1. 5.1 Global Combination Vaccine and Multivalent Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Combination Vaccine and Multivalent Vaccine Revenue by Type (2021-2032)
  3. 5.3 Global Combination Vaccine and Multivalent Vaccine Revenue Market Share by Type (2021-2032)
6 Combination Vaccine and Multivalent Vaccine Market Size by Application
  1. 6.1 Global Combination Vaccine and Multivalent Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Combination Vaccine and Multivalent Vaccine Revenue by Application (2021-2032)
  3. 6.3 Global Combination Vaccine and Multivalent Vaccine Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 BioNTech
  2. 7.1.1 BioNTech Company Information
  3. 7.1.2 BioNTech Business Overview
  4. 7.1.3 BioNTech Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (2021-2026)
  5. 7.1.4 BioNTech Combination Vaccine and Multivalent Vaccine Product Portfolio
  6. 7.1.5 BioNTech Recent Developments
  7. 7.2 Dynavax
  8. 7.2.1 Dynavax Company Information
  9. 7.2.2 Dynavax Business Overview
  10. 7.2.3 Dynavax Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Dynavax Combination Vaccine and Multivalent Vaccine Product Portfolio
  12. 7.2.5 Dynavax Recent Developments
  13. 7.3 Moderna
  14. 7.3.1 Moderna Company Information
  15. 7.3.2 Moderna Business Overview
  16. 7.3.3 Moderna Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Moderna Combination Vaccine and Multivalent Vaccine Product Portfolio
  18. 7.3.5 Moderna Recent Developments
  19. 7.4 Novavax
  20. 7.4.1 Novavax Company Information
  21. 7.4.2 Novavax Business Overview
  22. 7.4.3 Novavax Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Novavax Combination Vaccine and Multivalent Vaccine Product Portfolio
  24. 7.4.5 Novavax Recent Developments
  25. 7.5 Pfizer
  26. 7.5.1 Pfizer Company Information
  27. 7.5.2 Pfizer Business Overview
  28. 7.5.3 Pfizer Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Pfizer Combination Vaccine and Multivalent Vaccine Product Portfolio
  30. 7.5.5 Pfizer Recent Developments
  31. 7.6 Sanofi Pasteur
  32. 7.6.1 Sanofi Pasteur Company Information
  33. 7.6.2 Sanofi Pasteur Business Overview
  34. 7.6.3 Sanofi Pasteur Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Sanofi Pasteur Combination Vaccine and Multivalent Vaccine Product Portfolio
  36. 7.6.5 Sanofi Pasteur Recent Developments
  37. 7.7 AIM Bio
  38. 7.7.1 AIM Bio Company Information
  39. 7.7.2 AIM Bio Business Overview
  40. 7.7.3 AIM Bio Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (2021-2026)
  41. 7.7.4 AIM Bio Combination Vaccine and Multivalent Vaccine Product Portfolio
  42. 7.7.5 AIM Bio Recent Developments
  43. 7.8 Beijing Institute of Biological Products
  44. 7.8.1 Beijing Institute of Biological Products Company Information
  45. 7.8.2 Beijing Institute of Biological Products Business Overview
  46. 7.8.3 Beijing Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Beijing Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio
  48. 7.8.5 Beijing Institute of Biological Products Recent Developments
  49. 7.9 Chengdu Institute of Biological Products
  50. 7.9.1 Chengdu Institute of Biological Products Company Information
  51. 7.9.2 Chengdu Institute of Biological Products Business Overview
  52. 7.9.3 Chengdu Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Chengdu Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio
  54. 7.9.5 Chengdu Institute of Biological Products Recent Developments
  55. 7.10 Antejin Biotechnology
  56. 7.10.1 Antejin Biotechnology Company Information
  57. 7.10.2 Antejin Biotechnology Business Overview
  58. 7.10.3 Antejin Biotechnology Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Antejin Biotechnology Combination Vaccine and Multivalent Vaccine Product Portfolio
  60. 7.10.5 Antejin Biotechnology Recent Developments
  61. 7.11 GlaxoSmithKline
  62. 7.11.1 GlaxoSmithKline Company Information
  63. 7.11.2 GlaxoSmithKline Business Overview
  64. 7.11.3 GlaxoSmithKline Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (2021-2026)
  65. 7.11.4 GlaxoSmithKline Combination Vaccine and Multivalent Vaccine Product Portfolio
  66. 7.11.5 GlaxoSmithKline Recent Developments
  67. 7.12 Kangtai Bio
  68. 7.12.1 Kangtai Bio Company Information
  69. 7.12.2 Kangtai Bio Business Overview
  70. 7.12.3 Kangtai Bio Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Kangtai Bio Combination Vaccine and Multivalent Vaccine Product Portfolio
  72. 7.12.5 Kangtai Bio Recent Developments
  73. 7.13 Sinovac
  74. 7.13.1 Sinovac Company Information
  75. 7.13.2 Sinovac Business Overview
  76. 7.13.3 Sinovac Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Sinovac Combination Vaccine and Multivalent Vaccine Product Portfolio
  78. 7.13.5 Sinovac Recent Developments
  79. 7.14 Lanzhou Institute of Biological Products
  80. 7.14.1 Lanzhou Institute of Biological Products Company Information
  81. 7.14.2 Lanzhou Institute of Biological Products Business Overview
  82. 7.14.3 Lanzhou Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Lanzhou Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio
  84. 7.14.5 Lanzhou Institute of Biological Products Recent Developments
  85. 7.15 Minhai Biological
  86. 7.15.1 Minhai Biological Company Information
  87. 7.15.2 Minhai Biological Business Overview
  88. 7.15.3 Minhai Biological Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Minhai Biological Combination Vaccine and Multivalent Vaccine Product Portfolio
  90. 7.15.5 Minhai Biological Recent Developments
  91. 7.16 Merck & Co.
  92. 7.16.1 Merck & Co. Company Information
  93. 7.16.2 Merck & Co. Business Overview
  94. 7.16.3 Merck & Co. Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Merck & Co. Combination Vaccine and Multivalent Vaccine Product Portfolio
  96. 7.16.5 Merck & Co. Recent Developments
  97. 7.17 Wanbangde Pharmaceutical
  98. 7.17.1 Wanbangde Pharmaceutical Company Information
  99. 7.17.2 Wanbangde Pharmaceutical Business Overview
  100. 7.17.3 Wanbangde Pharmaceutical Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (2021-2026)
  101. 7.17.4 Wanbangde Pharmaceutical Combination Vaccine and Multivalent Vaccine Product Portfolio
  102. 7.17.5 Wanbangde Pharmaceutical Recent Developments
  103. 7.18 Wantai Biological
  104. 7.18.1 Wantai Biological Company Information
  105. 7.18.2 Wantai Biological Business Overview
  106. 7.18.3 Wantai Biological Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Wantai Biological Combination Vaccine and Multivalent Vaccine Product Portfolio
  108. 7.18.5 Wantai Biological Recent Developments
  109. 7.19 Walvax
  110. 7.19.1 Walvax Company Information
  111. 7.19.2 Walvax Business Overview
  112. 7.19.3 Walvax Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Walvax Combination Vaccine and Multivalent Vaccine Product Portfolio
  114. 7.19.5 Walvax Recent Developments
  115. 7.20 Wuhan Institute of Biological Products
  116. 7.20.1 Wuhan Institute of Biological Products Company Information
  117. 7.20.2 Wuhan Institute of Biological Products Business Overview
  118. 7.20.3 Wuhan Institute of Biological Products Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Wuhan Institute of Biological Products Combination Vaccine and Multivalent Vaccine Product Portfolio
  120. 7.20.5 Wuhan Institute of Biological Products Recent Developments
  121. 7.21 Zhifei Biological
  122. 7.21.1 Zhifei Biological Company Information
  123. 7.21.2 Zhifei Biological Business Overview
  124. 7.21.3 Zhifei Biological Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (2021-2026)
  125. 7.21.4 Zhifei Biological Combination Vaccine and Multivalent Vaccine Product Portfolio
  126. 7.21.5 Zhifei Biological Recent Developments
  127. 7.22 Sino Biopharm
  128. 7.22.1 Sino Biopharm Company Information
  129. 7.22.2 Sino Biopharm Business Overview
  130. 7.22.3 Sino Biopharm Combination Vaccine and Multivalent Vaccine Revenue and Gross Margin (2021-2026)
  131. 7.22.4 Sino Biopharm Combination Vaccine and Multivalent Vaccine Product Portfolio
  132. 7.22.5 Sino Biopharm Recent Developments
8 North America
  1. 8.1 North America Combination Vaccine and Multivalent Vaccine Revenue (2021-2032)
  2. 8.2 North America Combination Vaccine and Multivalent Vaccine Revenue by Type (2021-2032)
  3. 8.2.1 North America Combination Vaccine and Multivalent Vaccine Revenue by Type (2021-2026)
  4. 8.2.2 North America Combination Vaccine and Multivalent Vaccine Revenue by Type (2027-2032)
  5. 8.3 North America Combination Vaccine and Multivalent Vaccine Revenue Share by Type (2021-2032)
  6. 8.4 North America Combination Vaccine and Multivalent Vaccine Revenue by Application (2021-2032)
  7. 8.4.1 North America Combination Vaccine and Multivalent Vaccine Revenue by Application (2021-2026)
  8. 8.4.2 North America Combination Vaccine and Multivalent Vaccine Revenue by Application (2027-2032)
  9. 8.5 North America Combination Vaccine and Multivalent Vaccine Revenue Share by Application (2021-2032)
  10. 8.6 North America Combination Vaccine and Multivalent Vaccine Revenue by Country
  11. 8.6.1 North America Combination Vaccine and Multivalent Vaccine Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Combination Vaccine and Multivalent Vaccine Revenue by Country (2021-2026)
  13. 8.6.3 North America Combination Vaccine and Multivalent Vaccine Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Combination Vaccine and Multivalent Vaccine Revenue (2021-2032)
  2. 9.2 Europe Combination Vaccine and Multivalent Vaccine Revenue by Type (2021-2032)
  3. 9.2.1 Europe Combination Vaccine and Multivalent Vaccine Revenue by Type (2021-2026)
  4. 9.2.2 Europe Combination Vaccine and Multivalent Vaccine Revenue by Type (2027-2032)
  5. 9.3 Europe Combination Vaccine and Multivalent Vaccine Revenue Share by Type (2021-2032)
  6. 9.4 Europe Combination Vaccine and Multivalent Vaccine Revenue by Application (2021-2032)
  7. 9.4.1 Europe Combination Vaccine and Multivalent Vaccine Revenue by Application (2021-2026)
  8. 9.4.2 Europe Combination Vaccine and Multivalent Vaccine Revenue by Application (2027-2032)
  9. 9.5 Europe Combination Vaccine and Multivalent Vaccine Revenue Share by Application (2021-2032)
  10. 9.6 Europe Combination Vaccine and Multivalent Vaccine Revenue by Country
  11. 9.6.1 Europe Combination Vaccine and Multivalent Vaccine Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Combination Vaccine and Multivalent Vaccine Revenue by Country (2021-2026)
  13. 9.6.3 Europe Combination Vaccine and Multivalent Vaccine Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Combination Vaccine and Multivalent Vaccine Revenue (2021-2032)
  2. 10.2 China Combination Vaccine and Multivalent Vaccine Revenue by Type (2021-2032)
  3. 10.2.1 China Combination Vaccine and Multivalent Vaccine Revenue by Type (2021-2026)
  4. 10.2.2 China Combination Vaccine and Multivalent Vaccine Revenue by Type (2027-2032)
  5. 10.3 China Combination Vaccine and Multivalent Vaccine Revenue Share by Type (2021-2032)
  6. 10.4 China Combination Vaccine and Multivalent Vaccine Revenue by Application (2021-2032)
  7. 10.4.1 China Combination Vaccine and Multivalent Vaccine Revenue by Application (2021-2026)
  8. 10.4.2 China Combination Vaccine and Multivalent Vaccine Revenue by Application (2027-2032)
  9. 10.5 China Combination Vaccine and Multivalent Vaccine Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Combination Vaccine and Multivalent Vaccine Revenue (2021-2032)
  2. 11.2 Asia Combination Vaccine and Multivalent Vaccine Revenue by Type (2021-2032)
  3. 11.2.1 Asia Combination Vaccine and Multivalent Vaccine Revenue by Type (2021-2026)
  4. 11.2.2 Asia Combination Vaccine and Multivalent Vaccine Revenue by Type (2027-2032)
  5. 11.3 Asia Combination Vaccine and Multivalent Vaccine Revenue Share by Type (2021-2032)
  6. 11.4 Asia Combination Vaccine and Multivalent Vaccine Revenue by Application (2021-2032)
  7. 11.4.1 Asia Combination Vaccine and Multivalent Vaccine Revenue by Application (2021-2026)
  8. 11.4.2 Asia Combination Vaccine and Multivalent Vaccine Revenue by Application (2027-2032)
  9. 11.5 Asia Combination Vaccine and Multivalent Vaccine Revenue Share by Application (2021-2032)
  10. 11.6 Asia Combination Vaccine and Multivalent Vaccine Revenue by Country
  11. 11.6.1 Asia Combination Vaccine and Multivalent Vaccine Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Combination Vaccine and Multivalent Vaccine Revenue by Country (2021-2026)
  13. 11.6.3 Asia Combination Vaccine and Multivalent Vaccine Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Combination Vaccine and Multivalent Vaccine Revenue (2021-2032)
  2. 12.2 SAMEA Combination Vaccine and Multivalent Vaccine Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Combination Vaccine and Multivalent Vaccine Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Combination Vaccine and Multivalent Vaccine Revenue by Type (2027-2032)
  5. 12.3 SAMEA Combination Vaccine and Multivalent Vaccine Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Combination Vaccine and Multivalent Vaccine Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Combination Vaccine and Multivalent Vaccine Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Combination Vaccine and Multivalent Vaccine Revenue by Application (2027-2032)
  9. 12.5 SAMEA Combination Vaccine and Multivalent Vaccine Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Combination Vaccine and Multivalent Vaccine Revenue by Country
  11. 12.6.1 SAMEA Combination Vaccine and Multivalent Vaccine Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Combination Vaccine and Multivalent Vaccine Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Combination Vaccine and Multivalent Vaccine Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst